Devonian Health Group Inc.GSD.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · groupedevonian.com
Devonian Health Group Inc. is a Quebec-based clinical-stage pharmaceutical company specializing in the development of botanical drugs derived from plant materials and algae for the treatment of autoimmune and fibroinflammatory conditions. Its lead product candidate Thykamine is in clinical trials for atopic dermatitis and ulcerative colitis, utilizing the company's proprietary extraction and stabilization technology.
Key ratios
FCF / Sales
-95.2%TTM
2025
-5.4%2024
29.2%2023
-185.7%
Net margin
-88.2%TTM
2025
-25.5%2024
-9.5%2023
-196.1%
ROA
-14.0%TTM
2025
-2.1%2024
-1.5%2023
-13.3%
ROE
-83.4%TTM
2025
-52.3%2024
-13.0%2023
-30.1%
Recent news
Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American
Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay
Devonian Health Group Anticipates to Commence Trading on the NYSE American
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING
Track GSD.V in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer